About Catalent
Catalent is a Healthcare company based in Somerset (United States) founded in 2007, and was acquired by Novo Holdings in February 2024. CDMO offering drug and biologics development services. Catalent has completed 13 acquisitions, including Accucaps, Bettera and Cook Pharmica. Its chief executive, as recorded, is Alessandro Maselli. Its website catalent.com draws about 117 thousand monthly visits. Catalent offers products and services including Oral Dose Development, Softgel Technology, and Inhalation Development. Its focus areas include Biopharma Outsourcing, Diversified and Biologics. Its legal entity is Catalent, Inc. Its competitors include Surrozen, Curia and AmplifyBio; 2 of its 3 listed competitors have raised funding.
Company details
Catalent, backed by 202366937.14725998 from European Union, JPMorgan Chase, Aisling Capital, focuses on providing healthcare solutions, biopharma outsourcing, diversified, and biologics. CDMO offering drug and biologics development services. Driving innovation, growth, and excellence in its industry sectors. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Somerset, United States
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website catalent.com
- Social LinkedIn X Facebook YouTube
- Acquired by Novo Holdings (Feb 2024)
- Legal Name Catalent, Inc
- Latest Funding Round$761.61K (USD), Grant
Oct 2020
- InvestorsJPMorgan Chase
& 3 more
- Investments & AcquisitionsAccucaps
& 12 more
- Acquired byNovo Holdings
(Feb 2024)
Products & Services of Catalent
Catalent offers a comprehensive portfolio of products and services, including Oral Dose Development, Softgel Technology, and Inhalation Development.
Services for formulating and enhancing oral drug bioavailability.
Encapsulation solutions for improved drug delivery and stability.
Analytical and formulation services for inhalable drug forms.
Apps and channels of Catalent
its YouTube channel Catalent Pharma Solutions has 7.59K subscribers and 30 videos.
Videos from Catalent
The most watched videos on Catalent's YouTube channel, Catalent Pharma Solutions (7.59K subscribers). Click a video to play it here.
More on Catalent Pharma Solutions.
Funding Insights of Catalent
- Total Rounds 4
- Last Round Grant — $761,612
- Investors Count 3
All 4 funding rounds of Catalent with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2020 | $761,612 | Grant | – | – | |
| Feb 2020 | $200M | Debt – Conventional | – | – | |
| May 2015 | $1.61M | Grant | – | – | |
| Jun 2007 | Seed | – | Aisling Capital | – |
4 investors in total: 4 institutional.
Investors in Catalent
Catalent has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include JPMorgan Chase, European Union and Aisling Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Financial services are provided to consumers and corporations worldwide. | 2000 | jpmorganchase.com | New York, United States |
Investor details for Catalent
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Catalent
552 people are tracked at Catalent (207 in leadership, 345 in team).
| Name | Role | Group |
|---|---|---|
Marie-France Tschudin | Board of Directors | Leadership |
Susan Mahony | Board Director | Leadership |
Alessandro Maselli | CEO & President | Leadership |
Jonathan Levy | Board Member | Leadership |
Charles Patten | Board Member | Leadership |
Tim Walbert | Board Member | Leadership |
Amanda Ryder | Director Of Quality | Leadership |
Sabrina Huang | Human Resources Director | Leadership |
Steve Mezzano | Director Of Talent Acquisition | Leadership |
Tobias Zobel | Head Of Production | Leadership |
Donia Boucher-Slimani | Director Of Business Development, Core Biologics | Leadership |
Julie Delaney | Site Director Catalent Singapore | Leadership |
Lakisha Lavender | Associate Director Of Manufacturing | Leadership |
Tom Salus | Senior Account Director, Clinical Development & Supply | Leadership |
Todd Stutzman | Director | Leadership |
Jonathan Wilson | Senior Director Supply Chain | Leadership |
Drew Cheers | Head Of Finance, Core Biologics | Leadership |
Alessandra Matas | Human Resources Director | Leadership |
Sarah McLaughlin | Director Of Quality | Leadership |
Kamyar Bayat | Director Of Operations | Leadership |
532 more people are available in the full profile.
Complete people profiles for Catalent
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Catalent
Catalent has strategically engaged in corporate development activities, having acquired 13 companies. Notable acquisitions include Accucaps, Bettera and Cook Pharmica.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Oral dosage forms are developed and manufactured by the CDMO. | metricscontractservices.com | Greenville, United States | 1994 | Aug 2022 | $475M | |
Vaccine development is advanced by VMIC as a non-profit entity. | vmicuk.com | Oxford, United Kingdom | 2018 | Apr 2022 | •••• | |
Gummies and lozenges products are manufactured as core activities. | bettera.com | Plano, United States | 2009 | Aug 2021 | $1B | |
iPS cells are developed for therapeutics to prevent immune rejection. | rheincell.de | Langenfeld, Germany | 2017 | Jun 2021 | •••• | |
Provider of research services in molecular biology, protein engineering, and antibody development | delphigenetics.com | Charleroi, Belgium | 2001 | Feb 2021 | •••• | |
Services for cell therapy development and manufacturing are provided. | masthercell.com | Charleroi, Belgium | 2011 | Feb 2020 | $315M | |
Therapeutic proteins, disease biomarkers, vaccines and reagents for diagnostics | paragonbioservices.com | Baltimore, United States | 1990 | Apr 2019 | $1.2B | |
Specialty company developing therapeutics for women's health and a CDMO specializing in formulation development, analytical services and clinical manufacturing. | juniperpharma.com | Boston, United States | 1986 | Jul 2018 | •••• | |
Contract development and manufacturing services are provided to biopharmaceutical firms. | cookpharmica.com | Bloomington, United States | 2004 | Oct 2017 | $950M | |
Softgel formulations are contract developed and manufactured. | accucaps.com | Windsor, Canada | 1989 | Nov 2016 | •••• |
Complete acquisition details for Catalent
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Catalent
15 dated milestones of Catalent across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Catalent is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Accucaps.
- Acquisition Acquires Cook Pharmica.
- Acquisition Acquires Juniper Pharma.
- Acquisition Acquires Paragon Bioservices.
- Acquisition Acquires MaSTherCell.
- Funding Latest funding round, Grant, of $762K.
- Acquisition Acquires Delphi Genetics.
- Acquisition Acquires Rheincell Therapeutics.
- Acquisition Acquires Bettera.
- Acquisition Acquires VMIC UK.
- Acquisition Acquires Metrics Contract Services.
- Exit Acquired by Novo Holdings.
Competitors of Catalent
Catalent has 3 listed competitors in our database, 2 of them funded. They include Surrozen, Curia and AmplifyBio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| surrozen.com | 2016 | San Francisco, United States | $133M | 80 | Selective Wnt agonists are developed for human tissue regeneration. | |
| curiaglobal.com | 1991 | Albany, United States | 1,918 | Drug research, development, testing, and consulting services are provided. | ||
| amplify-bio.com | 2021 | Hilliard, United States | $229.75M | Provides contract research, development, and manufacturing services for biologic drugs. |
Detailed competitors of Catalent
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Catalent
The website of Catalent (catalent.com) receives about 116.7K visits a month and ranks #338,870 among all websites worldwide, #280 in Biotechnology and Pharmaceuticals.
- Monthly visits116.7K
▲ 6.1% vs previous month
- Unique visitors44.7K
per month
- Global rank#338,870
among all websites
- Category rank#280
Health · Biotechnology and Pharmaceuticals
- Bounce rate49%
- Pages per visit2.7
- Average visit1 min 05 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Catalent. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
theconferenceforum.org | theconferenceforum.org | 100% | #1,939,042 | – | |
| mazetx.com | 95% | 9.2K | #2,405,150 | View details | |
| nektar.com | 92% | 19.6K | #959,308 | View details | |
| pharmalex.com | 91% | 19.2K | #1,430,341 | View details | |
| recipharm.com | 90% | 21.8K | #1,103,989 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Catalent
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Catalent (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Catalent
Complete news archive for Catalent
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Catalent
Catalent was founded in 2007.
Catalent is headquartered in Somerset, United States.
Alessandro Maselli is the CEO of Catalent, as recorded in our data.
Catalent, backed by 202366937.14725998 from European Union, JPMorgan Chase, Aisling Capital, focuses on providing healthcare solutions, biopharma outsourcing, diversified, and biologics. CDMO offering drug and biologics development services. Driving innovation, growth, and excellence in its industry sectors. It continues to evolve, meeting industry challenges with strategic approaches.
Catalent's top competitors include Surrozen, Curia and AmplifyBio.
Catalent offers Oral Dose Development, Softgel Technology, and Inhalation Development.
Catalent has made 13 acquisitions, including Accucaps, Bettera, and Cook Pharmica.
Catalent has 4 investors. Key investors include JPMorgan Chase, European Union, Aisling Capital, and Novo Holdings.
Catalent operates through Catalent, Inc.
Yes. Catalent was acquired by Novo Holdings in February 2024.
The website of Catalent receives about 117 thousand visits a month and ranks #338,870 among all websites worldwide.